Holen Sie sich die Stockscreener-App
0.00
100.00%
-8.68
Schlusskurs vom Vortag:
$8.68
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$544.94M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
0.00
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$9.36
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
0.00 | 544.94M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Eingeleitet | Citigroup | Sell |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Postpartum Depression Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers - Barchart.com
How Sage Therapeutics Inc. stock compares to industry benchmarksInsider Selling & Free Expert Verified Stock Movement Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock enhance shareholder valueJuly 2025 Review & Technical Pattern Alert System - Newser
How big funds are accumulating Sage Therapeutics Inc. (SG7) stockStop Loss & Precise Swing Trade Alerts - Newser
Will Sage Therapeutics Inc. (SG7) stock outperform small cap peersDip Buying & Long-Term Safe Investment Ideas - Newser
Why Sage Therapeutics Inc. stock remains a top recommendationJuly 2025 Closing Moves & Safe Entry Zone Tips - Newser
How Sage Therapeutics Inc. (SG7) stock benefits from digital adoptionJuly 2025 Selloffs & Breakout Confirmation Trade Signals - Newser
What is the fair value of Sage Therapeutics Inc. stock now2025 Momentum Check & Consistent Profit Trading Strategies - Newser
Is Sage Therapeutics Inc. stock a buy on dips2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - BỘ NỘI VỤ
What analysts say about Sage Therapeutics Inc stockInsider Trading Compliance & High Return Wealth Building - earlytimes.in
Is Sage Therapeutics Inc. (SG7) stock undervalued after correctionWeekly Gains Summary & Real-Time Volume Spike Alerts - newser.com
What technical patterns form on Sage Therapeutics Inc. (SG7) stock chartsRate Cut & Weekly Market Pulse Updates - newser.com
How Sage Therapeutics Inc. stock benefits from global expansionJuly 2025 Drop Watch & Advanced Technical Signal Analysis - newser.com
Can Sage Therapeutics Inc. (SG7) stock resist broad market declines2025 Trading Recap & AI Forecast for Swing Trade Picks - newser.com
Is Sage Therapeutics Inc. (SG7) stock a buy during volatile marketsTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Can Sage Therapeutics Inc. (SG7) stock sustain revenue momentumWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Sage Therapeutics Inc. stock momentum explainedJuly 2025 WrapUp & Fast Gain Stock Tips - newser.com
Sage Therapeutics Inc. stock prediction for this weekWeekly Trade Summary & Consistent Profit Focused Trading Strategies - newser.com
Will Sage Therapeutics Inc. benefit from macro trends2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Will Sage Therapeutics Inc. (SG7) stock beat value stocks2025 Volume Leaders & Reliable Entry Point Alerts - newser.com
Why Sage Therapeutics Inc. (SG7) stock stays on top picks2025 Volatility Report & Precise Swing Trade Entry Alerts - newser.com
How Sage Therapeutics Inc. stock compares to growth peers2025 Technical Patterns & Growth Focused Stock Pick Reports - newser.com
Will Sage Therapeutics Inc. stock recover after recent dropWeekly Risk Report & Capital Efficiency Focused Strategies - newser.com
Published on: 2025-11-16 05:15:30 - newser.com
Sage Therapeutics Inc SG7 Stock Analysis and ForecastEarnings Revision Updates & Free Stock Trading Workshops - earlytimes.in
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):